

GULF MEDICAL PROJECTS COMPANY
PUBLIC SHAREHOLDING COMPANY

**REVIEW REPORT AND CONDENSED CONSOLIDATED
INTERIM FINANCIAL STATEMENTS FOR THE
THREE MONTHS PERIOD ENDED
31 MARCH 2025**

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim financial statements

For the three months period ended 31 March 2025

INDEX	<u>Page</u>	<u>Exhibit</u>
Review Report on Condensed Consolidated Interim Financial Statements	1	--
Condensed Consolidated Interim Statement of Financial Position	2	A
Condensed Consolidated Interim Statement of Income	3	B
Condensed Consolidated Interim Statement of Comprehensive Income	4	B (Continued)
Condensed Consolidated Interim Statement of Changes in Equity	5	C
Condensed Consolidated Interim Statement of Cash Flows	6	D
Notes to the Condensed Consolidated Interim Financial Statements	7 – 22	--

101380404

**Review Report on Condensed Consolidated Interim
Financial Statements to the Board of Directors of
Gulf Medical Projects Company
Public Shareholding Company**

Introduction

We have reviewed the accompanying condensed consolidated interim financial statements of **Gulf Medical Projects Company (PJSC)** (the “Company”) and **Its Subsidiary** (together referred to as the “Group”) which comprise the condensed consolidated interim statement of financial position as at 31 March 2025 and the condensed consolidated interim statement of income, comprehensive income, changes in equity and cash flows for the three-months period then ended, and other explanatory notes. Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with International Accounting Standard 34 “Interim Financial Reporting”. Our responsibility is to express a conclusion on this condensed consolidated interim financial statements based on our review.


Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements as at 31 March 2025 is not prepared, in all material respects, in accordance with IAS 34, ‘Interim Financial Reporting’.

TALAL ABU-GHAZALEH & CO. INTERNATIONAL



Zaid Ali Musleh
Licensed Auditor No. 1130

Sharjah, 14 May 2025

الاتحاد الدولي للمحاسبين (نيويورك)



MEMBER OF THE

FORUM OF FIRMS

عضو منتدى الشركات الكبرى في

Al Majaz 3, Al Ghanem Business Center
Office No. 301, 302
Tel.: +971 6 537 8800
Fax: +971 6 537 8811
P.O.Box: 952 Sharjah, United Arab Emirates



tagi.com

tagco.sharjah@tagi.com

منطقة المجاز ٣، مركز الغانم للأعمال
مكتب رقم ٣٠١، ٣٠٢
هاتف: +٩٧١ ٦ ٥٣٧ ٨٨٠٠
فاكس: +٩٧١ ٦ ٥٣٧ ٨٨١١
ص.ب: ٩٥٢ الشارقة، الإمارات العربية المتحدة

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim statement of financial position

As at 31 March 2025

Exhibit A

	Note	31 March 2025 (Unaudited) AED '000'	31 December 2024 (Audited) AED '000'
ASSETS			
Non-Current Assets			
Property and equipment	4	691,907	695,722
Intangible assets	5	609	735
Right-of-use assets	6	8,673	7,353
Investment properties	7	104,181	104,181
Investments at fair value through other comprehensive income (FVTOCI)	8	258,906	250,307
Total Non-Current Assets		1,064,276	1,058,298
Current Assets			
Inventories	9	20,517	18,047
Due from a related party	10	1,617	1,832
Investments at fair value through profit or loss (FVTPL)	8	40,105	36,567
Accounts receivable and others	11	107,528	128,088
Cash and bank balances	12	143,042	198,993
Total Current Assets		312,809	383,527
TOTAL ASSETS		1,377,085	1,441,825
Equity and Liabilities			
Equity			
Share capital	13	698,916	698,916
Reserves		306,223	306,223
Cumulative change in fair value of investments measured at fair value through other comprehensive income		27,046	18,447
Retained earnings		56,398	145,763
Net equity attributable to equity holders of the parent company		1,088,583	1,169,349
Non-controlling interest	14	97,458	91,033
Total Equity - Exhibit C		1,186,041	1,260,382
Non-Current Liabilities			
Employees' end of service benefits	15	29,338	28,102
Lease liabilities	16	4,420	4,420
Deferred tax liabilities	22	1,241	923
Total Non-Current Liabilities		34,999	33,445
Current Liabilities			
Accounts payable and others	17	142,374	138,317
Lease liabilities	16	3,251	1,500
Income tax provision	22	10,420	8,181
Total Current Liabilities		156,045	147,998
TOTAL EQUITY AND LIABILITIES		1,377,085	1,441,825

**THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

To the best of our knowledge, the financial information included in these condensed consolidated interim financial statements fairly presents in all material respects the financial condition, result of operation and cash flows of the Group as of, and for, the period presented therein.

These condensed consolidated interim financial statements were approved for issue by the Board of Directors on 14 May 2025 and signed on their behalf by :


 Sheikh Dr. Faisal Bin Khalid Khalid Al Qasimi
 (Chairman)

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim statement of income

For the three months period ended 31 March 2025 (Unaudited)

EXHIBIT B

	<u>Note</u>	<u>Three months period ended</u>	
		<u>31 March 2025</u> AED '000'	<u>31 March 2024</u> AED '000'
Revenues	19	180,053	167,051
Cost of revenues	20	(131,947)	(118,872)
Gross profit		48,106	48,179
Fair value gain/(loss) of investments at FVTPL		3,538	(510)
Other income		11,739	5,056
General and administrative expenses	21	(31,891)	(27,219)
Finance cost on lease liabilities		(38)	(43)
Profit for the period before tax -Exhibit D		31,454	25,463
Current income tax expenses	22	(2,239)	(2,255)
Deferred tax	22	(318)	--
Profit for the period		28,897	23,208
Attributable To :			
Equity holders of the parent company		22,472	16,828
Non-controlling interest		6,425	6,380
Total		28,897	23,208
Basic earnings per share (AED)	23	0.032	0.024

**THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim statement of comprehensive income

For the three months period ended 31 March 2025 (Unaudited) **EXHIBIT B (CONTINUED)**

	<u>Three months period ended</u>	
	<u>31 March 2025</u>	<u>31 March 2024</u>
	AED '000'	AED '000'
Profit for the period	28,897	23,208
Other comprehensive income :		
<i>Items that will not be reclassified subsequently to profit or loss:</i>		
Gain on sale of investments at FVTOCI	--	1,901
Increase/(decrease) in fair value of investments at FVTOCI	8,599	(519)
Net other comprehensive income	8,599	1,382
Total comprehensive income for the period – Exhibit C	37,496	24,590
Attributable to :		
Equity holders of the parent company	31,071	18,210
Non-controlling interest	6,425	6,380
Total	37,496	24,590

**THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

GULF MEDICAL PROJECTS COMPANY (PJSC)

Condensed consolidated interim statement of changes in equity
For the three months period ended 31 March 2025 (Unaudited)

EXHIBIT C

	Attributable to equity holders of the parent company						
	Share capital AED '000'	Reserves AED '000'	Cumulative change in fair value of investments at - FVTOCI AED '000'	Retained earnings AED '000'	Total AED '000'	Non-controlling interest AED '000'	Total AED '000'
Balance at 1 January 2024 (Audited)	698,916	298,434	(49,163)	159,078	1,107,265	68,870	1,176,135
Profit for the three months period ended 31 March 2024 - Exhibit B	--	--	--	16,828	16,828	6,380	23,208
Other comprehensive income	--	--	(519)	1,901	1,382	--	1,382
Total comprehensive income (Unaudited)	--	--	(519)	18,729	18,210	6,380	24,590
Cash dividends	--	--	--	(69,892)	(69,892)	--	(69,892)
Board of directors remuneration	--	--	--	(5,382)	(5,382)	--	(5,382)
Transfer of fair value reserve on disposal of investments at FVTOCI	--	--	8,696	(8,696)	--	--	--
Balance at 31 March 2024 (Unaudited)	698,916	298,434	(40,986)	93,837	1,050,201	75,250	1,125,451
Balance at 1 January 2025 (Audited)	698,916	306,223	18,447	145,763	1,169,349	91,033	1,260,382
Profit for the three months period ended 31 March 2025 - Exhibit B	--	--	--	22,472	22,472	6,425	28,897
Other comprehensive income	--	--	8,599	--	8,599	--	8,599
Total comprehensive income (Unaudited)	--	--	8,599	22,472	31,071	6,425	37,496
Cash dividends	--	--	--	(104,837)	(104,837)	--	(104,837)
Board of directors remuneration	--	--	--	(7,000)	(7,000)	--	(7,000)
Balance at 31 March 2025 (Unaudited) - Exhibit A	698,916	306,223	27,046	56,398	1,088,583	97,458	1,186,041

THE ACCOMPANYING NOTES CONSTITUTE AN
INTEGRAL PART OF THESE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

GULF MEDICAL PROJECTS COMPANY (PJSC)
Condensed consolidated interim statement of cash flows
For the three months period ended 31 March 2025 (Unaudited)

EXHIBIT D

	Three months period ended	
	31 March 2025	31 March 2024
	AED '000'	AED '000'
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit for the period before tax – Exhibit B	31,454	25,463
Adjustments for:		
Depreciation of property and equipment	6,774	6,210
Depreciation of right-of-use assets	643	609
Amortization of intangible assets	126	120
Fair value (gain)/loss on revaluation of investments at FVTPL	(3,538)	510
Dividends income	(3,234)	(2,016)
Loss from a related party	127	18
Provision for impairment loss of accounts receivable	8,684	6,881
Gain on sale of property and equipment	--	(1)
Employees end of service benefits	1,644	1,193
Finance costs – lease liabilities	38	43
Interest income	(1,916)	(902)
Operating cash flows before changes in operating assets and liabilities	40,802	38,128
Increase in inventories	(2,470)	(1,093)
Decrease/(increase) in due from a related party	88	(145)
Decrease/(increase) in accounts receivable and others	11,749	(57,306)
Increase in accounts payable and others	4,057	2,242
Settlements of employees end of service benefits	(408)	(768)
Net Cash Provided by/(Used in) Operating Activities	53,818	(18,942)
CASH FLOWS FROM INVESTING ACTIVITIES		
Decrease in fixed deposits	101,518	31,234
Interest income received	2,705	1,155
Purchase of property and equipment	(2,959)	(7,306)
Purchase of intangible assets	--	(303)
Proceeds from sale of property and equipment	--	1
Proceed from sale of investments at FVTOCI	--	46,879
Dividends received	2,572	2,016
Net Cash Provided by Investing Activities	103,836	73,676
CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of lease liabilities	(250)	(218)
Cash dividends paid	(104,837)	(69,892)
Board of directors remuneration paid	(7,000)	(5,382)
Net Cash Used in Financing Activities	(112,087)	(75,492)
Net increase/(decrease) in cash and cash equivalents	45,567	(20,758)
Cash and cash equivalents at beginning of period	22,952	48,857
Cash and Cash Equivalents at end of Period - Note 24	68,519	28,099

**THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

1. STATUS AND ACTIVITIES

Gulf Medical Projects Company – Sharjah (hereinafter referred to as the “**Company**”) is a public shareholding company incorporated in Sharjah by an Amiri Decree No. 48/79 issued by His Highness The Ruler of Sharjah on 2 August 1979.

The main activities of the Company and its subsidiary (together referred to as the “**Group**”) are general hospital, telehealth services and home health care center, advanced first aid training center, hospitals management and establishment of medicine manufacturing factories.

The Company is domiciled in Sharjah city and its registered address is P.O. Box: 5385, Sharjah, United Arab Emirates.

2. BASIS OF PREPARATION

2.1 Statement of compliance

The condensed consolidated interim financial statements for the three months period ended 31 March 2025 have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting”.

Condensed consolidated interim financial statements does not include all of the information and footnotes required for full annual consolidated financial statements prepared in accordance with International Financial Reporting Standards and should be read in conjunction with the Group’s annual consolidated audited financial statements as at and for the year ended 31 December 2024. In addition, results for the three months period ended 31 March 2025 for the Group are not necessarily indicative of the results that may be expected for the financial year ended 31 December 2025.

2.2 Basis of measurement

These condensed consolidated interim financial statements have been prepared on the historical cost basis except for investment properties, land and investment in financial assets which have been measured on the basis of fair value/valuation.

2.3 Functional and presentation currency

These condensed consolidated interim financial statements are presented in UAE Dirham (AED), which is the Group’s functional currency. Amounts in the condensed consolidated interim financial statements are rounded to the nearest Thousand Arab Emirates Dirham (AED ‘000’).

2.4 Use of estimates, assumptions and judgments

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that effect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

In preparing these condensed consolidated interim financial statements the significant judgments made by management in applying the accounting policies and the key sources of estimation uncertainty were the same as that were applied to consolidated financial statements for the year ended 31 December 2024.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

2. BASIS OF PREPARATION (CONTINUED)

2.5 Basis of consolidation

These condensed consolidated interim financial statements incorporate the condensed interim financial statements of the parent company and entity controlled by the Company (its subsidiary). Control is achieved when the Group has :

- The Group has power over the investee.
- The Group is exposed, or has rights, to variable returns from its involvement with the investee.
- The Group has the ability to use its power over the investee to affect its returns.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control mentioned above.

When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts circumstances whether it has power over an investee, including:

- The contractual arrangement with the other vote holders of the investee.
- Rights arising from other contractual arrangements.
- The Group's voting rights and potential voting rights

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed during the period is included in the condensed consolidated interim statement of income from the date the Group gains control until the date when the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributable to the equity holders of the parent company and to the non-controlling interest even if this results in the non-controlling interest having a deficit balance.

When necessary, adjustments are made to the financial statements of the subsidiary to bring their accounting policies into line with the Group accounting policies.

All intragroup balances and income, equity and cash flows relating to transactions between entities of the Group are eliminated in full on consolidation.

Changes in the Group ownership interests in the subsidiary that do not result in the Group losing control over the subsidiary is accounted for as equity transactions. The carrying amounts of the Group interests and the non-controlling interest are adjusted to reflect the changes in their relative interests in the subsidiary. Any difference between the amount by which the non-controlling interest are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to owners of the Group.

The details of the subsidiary is as follows :

<u>Company</u>	<u>% of ownership</u>		<u>Principal activities</u>	<u>Country of incorporation</u>
	<u>31 March 2025</u>	<u>31 December 2024</u>		
Al Zahra (Pvt.) Hospital Dubai (L.L.C)	68.38	68.38	General Hospital, home healthcare center and telehealth services and advance first aid training center.	UAE

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

3. MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies used in the preparation of these condensed consolidated interim financial statements are consistent with those used in the Group's audited annual consolidated financial statements for the year ended 31 December 2024.

The new revised relevant IFRSs effective from 1 January 2025 had no material impact on the condensed consolidated interim financial position or performance of the Group during the period.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

4. PROPERTY AND EQUIPMENT

a) The details of this item are as follows :

	<u>Land</u> AED '000'	<u>Hospital buildings</u> AED '000'	<u>Hospital furniture and equipment</u> AED '000'	<u>Motor vehicles</u> AED '000'	<u>Other furniture and equipment</u> AED '000'	<u>Capital work-in-progress</u> AED '000'	<u>Total</u> AED '000'
Cost/Revaluation :							
At 1 January 2024	250,482	578,632	151,628	4,666	16,823	748	1,002,979
Additions during the year	--	1,226	12,794	1,036	876	4,783	20,715
Disposals during the year	--	--	(1,922)	(739)	(170)	(162)	(2,993)
Transfer	--	2,504	--	--	--	(2,504)	--
At 31 December 2024	250,482	582,362	162,500	4,963	17,529	2,865	1,020,701
Additions during the period	--	116	2,743	--	100	--	2,959
Balance at 31 March 2025	250,482	582,478	165,243	4,963	17,629	2,865	1,023,660
Accumulated Depreciation :							
At 1 January 2024	--	159,838	122,015	3,351	15,875	--	301,079
Charged for the year	--	16,102	8,607	346	625	--	25,680
Relating to disposals	--	--	(1,474)	(139)	(167)	--	(1,780)
At 31 December 2024	--	175,940	129,148	3,558	16,333	--	324,979
Charged for the period	--	4,048	2,455	95	176	--	6,774
Balance at 31 March 2025	--	179,988	131,603	3,653	16,509	--	331,753
Net Book Value							
At 31 March 2025 - Exhibit A (Unaudited)	250,482	402,490	33,640	1,310	1,120	2,865	691,907
At 31 December 2024 - Exhibit A (Audited)	250,482	406,422	33,352	1,405	1,196	2,865	695,722

- b) Land of AED. 250,482 thousand mentioned above represents the fair value of a plot of land at date of acquisition measuring 350,000 square feet registered with the concerned government department in the name of the subsidiary.
- c) Capital work-in-progress of AED. 2,865 thousand mentioned above represent the costs incurred for the heat pumps and accessories at the hospital buildings in the Emirate of Dubai.
- d) Depreciation for the period is allocated to cost of revenues and general and administrative expenses amounting to AED. 6,677 thousand (At 31 March 2024 : AED. 6,114 thousand) and AED. 97 thousand (At 31 March 2024 : AED. 96 thousand), respectively.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

5. INTANGIBLE ASSETS

a) This item consists of the following :

	<u>Software</u> AED '000'
Cost	
At 1 January 2024	3,632
Additions	303
At 31 December 2024	3,935
Balance at 31 March 2025	3,935
Accumulated Amortization	
At 1 January 2024	2,672
Charged for the year	528
At 31 December 2024	3,200
Charged for the period	126
Balance at 31 March 2025	3,326
Net book Value	
At 31 March 2025 – Exhibit A (Unaudited)	609
At 31 December 2024 – Exhibit A (Audited)	735

b) Amortization for the period is allocated to cost of revenues and general administrative expenses amounting to AED. 125 thousand (At 31 March 2024 : AED. 119 thousand) and AED. 1 thousand (At 31 March 2024 : AED. 1 thousand) respectively.

6. RIGHT-OF-USE ASSETS

The movement of right-of-use assets are summarized as follows :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
At 1 January	7,353	9,789
Addition during the period/year	1,963	--
Charged for the period/year	(643)	(2,436)
Net balance at the end of the period/year – Exhibit A	8,673	7,353

7. INVESTMENT PROPERTIES

a) This item consists of the following :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Fair value at 1 January	104,181	91,091
Increase in fair value	--	13,090
Fair Value at end of the period/year – Exhibit A	104,181	104,181

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

7. INVESTMENT PROPERTIES (CONTINUED)

b) Investment properties of AED. 104,181 thousand mentioned above represent the fair value at the review report date as per management estimate.

c) Investment properties represent investments in land and real estates in the United Arab Emirates.

8. INVESTMENTS IN FINANCIAL ASSETS

Investments in financial assets comprise of the following :

a) Investments at fair value through other comprehensive income (FVTOCI)

This item consists of the following :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Fair value at 1 January	250,307	259,053
Sales during the period/year	--	(68,217)
Gain on sale of investments at FVTOCI	--	4,231
Increase in fair value	8,599	55,240
Fair value at end of the period/year – Exhibit A	258,906	250,307

Investments at fair value through other comprehensive income represent investments in securities quoted in the local financial markets.

b) Investments at fair value through profit or loss (FVTPL)

This item consists of the following :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Fair value at 1 January	36,567	39,406
Increase/(decrease) in fair value	3,538	(2,839)
Fair Value at end of the period/year - Exhibit A	40,105	36,567

Investments at fair value through profit or loss represent investment in securities quoted in local and regional financial markets.

9. INVENTORIES

This item consists of the following :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Goods for sale (drugs and cosmetics)	11,628	9,851
General stores and hospital supplies	9,479	8,786
Provision for slow-moving items	(590)	(590)
Net Amount – Exhibit A	20,517	18,047

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

10. BALANCES AND TRANSACTIONS WITH RELATED PARTIES

In the normal course of business, the Group enters into various transactions with related parties. Related parties represent major shareholders, directors and key management personnel of the group, and entities controlled, jointly controlled or significantly influenced by such parties. The prices and terms of these transactions are agreed with the Group's management.

- **Due from a related party**

This item represents the amount due from Gulf Medical Commercial Agencies (LLC) – Sharjah. As per the management contract the Company is managed and financed by the Group in return for obtaining all the profit/(losses) generated by the Company which has been included in the condensed consolidated interim statement of income for the Group. The details of the movement in this account are as follows :

	31 March 2025 (Unaudited) AED '000'	31 December 2024 (Audited) AED '000'
Balance at 1 January	1,832	2,193
Net funds (paid)/received	(88)	9
Loss for the period/year transferred	(127)	(370)
Balance at end of the period/year – Exhibit A	1,617	1,832

- The following are the details of significant related parties transactions :

	Three months period ended 31 March 2025 (Unaudited) AED '000'	31 March 2024 (Unaudited) AED '000'
Purchases	130	217
Expenses	133	133

- The remuneration, salaries and other benefits of Board of Directors and other members of key management during the period are as follows :

	Three months period ended 31 March 2025 (Unaudited) AED '000'	31 March 2024 (Unaudited) AED '000'
Board of directors remuneration (as approved by the Annual General Meeting)	7,000	5,382
Key management salaries and other related benefits	2,522	2,542
Board committee expenses	47	122

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

11. ACCOUNTS RECEIVABLE AND OTHERS

a) This item consists of the following :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Accounts receivable	221,532	227,960
Provision for impairment loss of accounts receivable – Note 11(b)	(126,174)	(117,929)
Net Amount	95,358	110,031
Prepaid expenses	4,604	5,090
Recoverable tax (VAT)	1,170	2,536
Post-dated cheques received	518	596
Refundable deposits	1,215	1,215
Interest receivable	158	947
Staff receivables	343	342
Margin held with banks	999	999
Advances paid	2,417	1,507
Due from a local brokerage company	84	4,823
Others	662	2
Total - Exhibit A	107,528	128,088

b) The details of movement in provision for impairment loss of accounts receivable are as follows:

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Balance at 1 January	117,929	92,840
Addition during the period/year	8,684	30,467
Written off during the period/year	(439)	(5,378)
Balance at the end of the period/year – Note 11(a)	126,174	117,929

12. CASH AND BANK BALANCES

This item consists of the following :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Cash in hand	195	224
Bank balances - Current and call deposit accounts	68,324	22,728
Fixed deposits	74,523	176,041
Total - Exhibit A	143,042	198,993

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

13. SHARE CAPITAL

This item consists of the following :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Authorized share capital is 698,916,094 ordinary shares of AED. 1 each fully paid – Exhibit A	698,916	698,916

14. NON-CONTROLLING INTEREST

a) The details of movement in this item during the period/year are as follows :

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Balance at 1 January	91,033	68,870
Share of profit for the period/year	6,425	22,163
Balance at end of the period/year - Exhibit A	97,458	91,033

b) Non-controlling interest mentioned above represents the share of non-controlling as at the condensed consolidated interim statement of financial position date and are as follows:

	<u>31 March 2025</u> <u>(Unaudited)</u> %	<u>31 December 2024</u> <u>(Audited)</u> %
Share in Al Zahra (Pvt) Hospital Dubai (L.L.C)	31.62	31.62

15. EMPLOYEES' END OF SERVICE BENEFITS

The details of movement in this item during the period/year are as follows:

	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Balance at 1 January	28,102	25,027
Current service cost	1,644	5,296
Settlements	(408)	(2,221)
Balance at end of the period/year – Exhibit A	29,338	28,102

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

16. LEASE LIABILITIES

Lease liabilities represent the long term leases of staff accommodation and robotics surgical systems up to the year 2029. The details of movement in this item during the period/year are as follows :

	31 March 2025 (Unaudited) AED '000'	31 December 2024 (Audited) AED '000'
Balance at 1 January	5,920	8,115
Additions during the period/year	1,963	--
Interest on lease liabilities for the period/year	38	150
Payments during the period/year	(250)	(2,345)
Balance at the end of the period/year	7,671	5,920
Non-Current – Exhibit A	4,420	4,420
Current – Exhibit A	3,251	1,500
Total	7,671	5,920

17. ACCOUNTS PAYABLE AND OTHERS

This item consists of the following :

	31 March 2025 (Unaudited) AED '000'	31 December 2024 (Audited) AED '000'
Accounts payable	66,479	58,378
Uncollected portion of repayments to shareholders	1,070	1,070
Post -dated cheques issued	10,278	7,059
Accrued expenses	9,466	11,514
Provision for staff leave salaries and air passage	16,834	15,750
Income received in advance	2,497	2,727
Staff payables	27	161
Others	35,723	41,658
Total - Exhibit A	142,374	138,317

18. SEGMENT INFORMATION

The Board of Directors are chief operating decision makers. Management determine the operation segments based on segments identified for the purpose of allocation resources and assessing performance.

The Group's reportable segments are organized into two major segments as follows:

- i) Health services and others Principally providing health, medical care and other related services.
- ii) Investments Principally concerned with investment properties and investment in securities.

Performance of each segment is measured based on segment profit as management believes that profit is the most relevant factor in evaluating the results of segment.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

18. SEGMENT INFORMATION (CONTINUED)

The financial analysis according to the business segments are as follows :

	<u>Health Services & others</u>		<u>Investments</u>		<u>Total</u>	
	<u>Three months period ended</u>		<u>Three months period ended</u>		<u>Three months period ended</u>	
	<u>31 March 2025</u>	<u>31 March 2024</u>	<u>31 March 2025</u>	<u>31 March 2024</u>	<u>31 March 2025</u>	<u>31 March 2024</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>
Revenues						
Total revenues	<u>180,053</u>	<u>167,051</u>	<u>9,238</u>	<u>2,607</u>	<u>189,291</u>	<u>169,658</u>
Result						
Segment result	<u>48,106</u>	<u>48,179</u>	<u>9,189</u>	<u>2,494</u>	<u>57,295</u>	<u>50,673</u>
Unallocated general and administrative expenses					<u>(31,929)</u>	<u>(27,262)</u>
Operating profit					<u>25,366</u>	<u>23,411</u>
Other income	<u>6,088</u>	<u>2,052</u>	<u>--</u>	<u>--</u>	<u>6,088</u>	<u>2,052</u>
Profit from operation before tax					<u>31,454</u>	<u>25,463</u>
Current income tax expenses					<u>(2,239)</u>	<u>(2,255)</u>
Deferred tax					<u>(318)</u>	<u>--</u>
Profit from operation					<u>28,897</u>	<u>23,208</u>
Attributable to non-controlling interest					<u>(6,425)</u>	<u>(6,380)</u>
Profit for the period	<u>22,472</u>	<u>16,828</u>			<u>22,472</u>	<u>16,828</u>

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

18. SEGMENT INFORMATION (CONTINUED)

	<u>Health Services & others</u>		<u>Investments</u>		<u>Total</u>	
	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'	<u>31 March 2025</u> <u>(Unaudited)</u> AED '000'	<u>31 December 2024</u> <u>(Audited)</u> AED '000'
Other information						
Segment assets	911,697	882,495	465,388	559,330	1,377,085	1,441,825
Segment liabilities	184,039	175,147	7,005	6,296	191,044	181,443
Capital expenditure	2,959	21,018	--	--	2,959	21,018

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

19. REVENUES

a) This item consists of the following :

	Three months period ended	
	31 March 2025	31 March 2024
	(Unaudited)	(Unaudited)
	AED '000'	AED '000'
Revenue from contracts with customers - Exhibit B	180,053	167,051

b) Disaggregation of revenue from contracts with customers

Set out below is the disaggregation of the Group's revenue from contracts with customers :

	Three months period ended	
	31 March 2025	31 March 2024
	(Unaudited)	(Unaudited)
	AED '000'	AED '000'
<u>Segments</u>		
Type of services		
Revenue from healthcare services	180,053	167,051
Geographical markets		
Revenue within the UAE	180,053	167,051
Timing of revenue recognition		
Services and goods transferred at a point in time	180,053	167,051

c) Performance obligations

Information about the Group's performance obligations are summarized below :

Rendering of services

Health care services revenues primarily comprise fees charged for inpatient and outpatient medical services. Services include charges for accommodation, theatre, medical professional services, equipment, laboratory and pharmaceutical items used and recorded at the time of billing.

Sale of goods

Revenue from sale of goods represent the total revenue from sale of drug and cosmetics provided to customers and is recognized when control and benefits are transferred and billed.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

20. COST OF REVENUES

This item consists of the following :

	Three months period ended	
	<u>31 March 2025</u>	<u>31 March 2024</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	AED '000'	AED '000'
Salaries and other related benefits	78,983	71,004
Supplies and services	45,519	41,026
Depreciation of property and equipment	6,677	6,114
Depreciation of right-of-use assets	643	609
Amortization of intangible assets	125	119
Total - Exhibit B	131,947	118,872

21. GENERAL AND ADMINISTRATIVE EXPENSES

This item consists of the following :

	Three months period ended	
	<u>31 March 2025</u>	<u>31 March 2024</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	AED '000'	AED '000'
Staff salaries and other related benefits	15,518	13,581
Board committee expenses	47	122
Electricity and water	1,530	1,440
Advertising and publicity	1,064	603
Provision for impairment loss of accounts receivable	8,684	6,881
Government expenses	1,883	1,754
Telephone and postage	187	207
Insurance	379	371
Legal and professional fees	816	715
Banks and credit card charges	555	567
Depreciation of property and equipment	97	96
Amortization of intangible assets	1	1
Miscellaneous expenses	1,130	881
Total - Exhibit B	31,891	27,219

22. INCOME TAX

Corporate Tax Law

On 9 December 2022, the UAE Ministry of Finance released Federal Decree-Law No. 47 of 2022 on the Taxation of Corporations and Businesses, Corporate Tax Law ("CT Law") to enact a Federal corporate tax regime in the UAE. Furthermore, a Cabinet Decision was published which specifies that taxable income not exceeding AED. 375,000 would be subject to a 0% UAE CT rate and taxable income exceeding AED. 375,000 would be subject to the 9% UAE CT rate.

The effective implementation date for the Group start from 1 January 2024.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the three months period ended 31 March 2025

22. INCOME TAX (CONTINUED)

Corporate Tax Law (Continued)

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed consolidated interim statement of income are as follows :

Current income tax:

The movement in this item during the period/year are as follows:

	31 March 2025	31 December 2024
	(Unaudited)	(Audited)
	AED ‘000’	AED ‘000’
Balance at 1 January	8,181	--
Current tax expenses for the period/year	2,239	8,181
	<hr/>	<hr/>
Balance at end of the period/year – Exhibit A	10,420	8,181
	<hr/> <hr/>	<hr/> <hr/>

The income tax expenses for current period ended 31 March 2025 is AED. 2,239 thousand (31 March 2024: AED.2,255 thousand) - **Exhibit B** and the effective current income tax rate for the period 7.11% (31 March 2024: 8.86%)

Deferred tax:

The movement in this item during the period/year are as follows:

	31 March 2025	31 December 2024
	(Unaudited)	(Audited)
	AED ‘000’	AED ‘000’
Balance at 1 January	923	--
Deferred tax liabilities for the period/year	318	923
	<hr/>	<hr/>
Balance at end of the period/year – Exhibit A	1,241	923
	<hr/> <hr/>	<hr/> <hr/>

The deferred tax liabilities of AED.318 thousand (31 March 2024: AED Nil) - **Exhibit B**, as determined by the Group’s management assessment, arising from temporary differences related to the fair value changes in assets measured at fair value as of the condensed consolidated interim statement of financial position date.

GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements
For the three months period ended 31 March 2025

23. BASIC EARNINGS PER SHARE

This item consists of the following :

	Three months period ended 31 March 2025 (Unaudited)	31 March 2024 (Unaudited)
Profit for the period attributable to equity holders of the Parent Company (AED '000')	22,472	16,828
Weighted average number of shares (Share '000')	698,916	698,916
Basic earnings per share (AED) - Exhibit B	0.032	0.024

24. CASH AND CASH EQUIVALENTS

At 31 March 2025 and 2024 “cash and cash equivalents” included in the condensed consolidated interim statement of cash flows (Exhibit D) comprise the following items :

	Three months period ended 31 March 2025 (Unaudited) AED '000'	31 March 2024 (Unaudited) AED '000'
Cash in hand	195	251
Bank balances – Current and call accounts	68,324	27,848
Total - Exhibit D	68,519	28,099

25. DIVIDEND AND DIRECTORS' REMUNERATION

- At the Annual General Meeting held on 17 March 2025, the shareholders approved 15% cash dividend proposed by the Board of Directors.
- At the Annual General Meeting held on 17 March 2025, the shareholders approved the proposed Board of Directors' remuneration amounting to AED. 7,000 thousand for the year ended 31 December 2024.

26. CONTINGENT LIABILITIES/COMMITMENTS

i) *Contingent liabilities*

Contingent liabilities of the Group as at the condensed consolidated interim statement of financial position date amounted to AED. 999 thousand (Unaudited) [(31 December 2024: AED. 999 thousand) (Audited)] representing guarantees issued.

ii) *Commitments*

Commitments of the group as at the condensed consolidated interim statement of financial position date are as follows :

	31 March 2025 (Unaudited) AED '000'	31 December 2024 (Audited) AED '000'
Capital purchases	13,444	15,832